Instil Bio, Inc. (TIL) Stock Score, Valuation & Financial Research

Instil Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TIL

Instil Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 7.35. These figures are a research snapshot, not a buy or sell recommendation.

What Instil Bio, Inc. does

Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Instil Bio is a biotechnology company that focuses on identifying and advancing innovative therapeutic opportunities. The company is currently in the development stage and has not generated any revenue from product sales, relying instead on capital financing to fund its research and development operations.

Products and services

  • The company is a clinical-stage biotechnology firm focused on the development of therapeutic candidates. Following the discontinuation of its former lead candidate, AXN-2510, in January 2026, the company is evaluating new strategic opportunities.

Customer types

Clinical trial participants and healthcare providers.

Suppliers, materials and equipment

  • Contract Research Organizations and Contract Manufacturing Organizations — The company relies on various third-party service providers for clinical trial management and manufacturing services; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. — The company previously maintained a license and collaboration agreement for the development of AXN-2510, which was terminated in January 2026. Source

Business strengths to evaluate

  • Cash position sufficient to fund current operating plan beyond 2027 Source

Business risks and research considerations

  • History of operating losses and accumulated deficit Source
  • Dependence on third-party collaborators and service providers Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TIL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 7.35
Market capitalization:
49.85M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -30.28M
Free cash flow:
USD -36.62M
Cash:
USD 5.54M
Total debt:
USD 3.67M
EPS:
USD -4.47

What stands out

  • Free cash flow is USD -36.62M, negative for the stored period.
  • The balance sheet shows USD 5.54M of cash versus USD 3.67M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 1.87M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TIL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TIL fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is TIL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for TIL to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of TIL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research TIL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.